Vical Inc., of San Diego, priced its public offering of about 14.3 million shares at $1.75 apiece for gross proceeds of about $25 million. Vical granted sole underwriter H.C. Wainwright & Co. LLC a 30-day option to purchase up to an additional 2.14 million shares of common stock, which could add $3.7 million. The company, which works in the area of infectious disease, plans to use the net proceeds for general corporate purposes, including clinical trial expenses, R&D expenses, general and administrative expenses, manufacturing expenses and potential acquisitions. Shares of Vical (NASDAQ:VICL) closed Wednesday at $1.83, up 17 cents.